<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/C842A34F-18F7-454D-A259-FED802368496"><gtr:id>C842A34F-18F7-454D-A259-FED802368496</gtr:id><gtr:name>University of Leicester</gtr:name><gtr:department>Cancer Studies and Molecular Medicine</gtr:department><gtr:address><gtr:line1>University Road</gtr:line1><gtr:line4>Leicester</gtr:line4><gtr:line5>Leicestershire</gtr:line5><gtr:postCode>LE1 7RH</gtr:postCode><gtr:region>East Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/C842A34F-18F7-454D-A259-FED802368496"><gtr:id>C842A34F-18F7-454D-A259-FED802368496</gtr:id><gtr:name>University of Leicester</gtr:name><gtr:address><gtr:line1>University Road</gtr:line1><gtr:line4>Leicester</gtr:line4><gtr:line5>Leicestershire</gtr:line5><gtr:postCode>LE1 7RH</gtr:postCode><gtr:region>East Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/DB2F4CAA-1DCE-49BF-9DEA-79DA9C6B3264"><gtr:id>DB2F4CAA-1DCE-49BF-9DEA-79DA9C6B3264</gtr:id><gtr:firstName>Ian</gtr:firstName><gtr:surname>White</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0100875"><gtr:id>9B683F66-4426-48BA-99A9-0D2B1EE29929</gtr:id><gtr:title>Receptor mediated toxicity</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0100875</gtr:grantReference><gtr:abstractText>Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.</gtr:abstractText><gtr:fund><gtr:end>2007-03-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2002-04-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>725889</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>EAB82AC3-3241-473B-AC85-59A222C8F770</gtr:id><gtr:title>Ishikawa cells exhibit differential gene expression profiles in response to oestradiol or 4-hydroxytamoxifen.</gtr:title><gtr:parentPublicationTitle>Endocrine-related cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/96644ca220a8fc1cfe138891d97c92b9"><gtr:id>96644ca220a8fc1cfe138891d97c92b9</gtr:id><gtr:otherNames>Johnson SM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1351-0088</gtr:issn><gtr:outcomeId>cnUiwNJGgYb</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>78D5B98B-6F6E-4BA8-8639-9E7775D012CE</gtr:id><gtr:title>Neonatal administration of tamoxifen causes disruption of myometrial development but not adenomyosis in the C57/BL6J mouse.</gtr:title><gtr:parentPublicationTitle>Reproduction (Cambridge, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ec55224844144b1fe18df240e34d344a"><gtr:id>ec55224844144b1fe18df240e34d344a</gtr:id><gtr:otherNames>Mehasseb MK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1470-1626</gtr:issn><gtr:outcomeId>QDjdcspwmmz</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2F5FED39-3630-4358-8BEB-2676DAD4250D</gtr:id><gtr:title>Absence of uterine tumours in CD-1 mice treated neonatally with subcutaneous tamoxifen or 4-hydroxyoestradiol.</gtr:title><gtr:parentPublicationTitle>Experimental and toxicologic pathology : official journal of the Gesellschaft fur Toxikologische Pathologie</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2ed667175a4a36e33f9abcadf7159688"><gtr:id>2ed667175a4a36e33f9abcadf7159688</gtr:id><gtr:otherNames>Razvi N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0940-2993</gtr:issn><gtr:outcomeId>cyxkzUrc5d3</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C6C49BE9-501C-4E2C-B756-8391C625B2C9</gtr:id><gtr:title>Experimental adenomyosis.</gtr:title><gtr:parentPublicationTitle>Best practice &amp; research. Clinical obstetrics &amp; gynaecology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bf59a946805284437eb34e825b305cbb"><gtr:id>bf59a946805284437eb34e825b305cbb</gtr:id><gtr:otherNames>Greaves P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>1521-6934</gtr:issn><gtr:outcomeId>rDLDxAYSSTz</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9E50210A-A1CE-4F98-8C89-0EE0F01A4E81</gtr:id><gtr:title>The effects of tamoxifen and estradiol on myometrial differentiation and organization during early uterine development in the CD1 mouse.</gtr:title><gtr:parentPublicationTitle>Reproduction (Cambridge, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ec55224844144b1fe18df240e34d344a"><gtr:id>ec55224844144b1fe18df240e34d344a</gtr:id><gtr:otherNames>Mehasseb MK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1470-1626</gtr:issn><gtr:outcomeId>dMG3jUBm55W</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0100875</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>7C58A707-1BF6-4573-A44F-30B271C80813</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Cancer</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>8F896112-5A04-4A11-A9F0-2B446D9AAC8A</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>5.1  Pharmaceuticals</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>